Therapy Areas: Inflammatory Diseases
Bridge Biotherapeutics files IND for BBT-877 with US FDA for for treatment of Idiopathic Pulmonary Fibrosis
19 November 2018 - South Korean biotech company Bridge Biotherapeutics Inc disclosed on Monday that it has submitted its Investigational New Drug (IND) application with the US Food and Drug Administra...
Immunicum enters into collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate Ilixadencel in combination with Avelumab
19 November 2018 - Immunicum AB (STO:IMMU.ST), a biomedical company engaged in the development of cancer immunotherapies, on Friday announced that it has entered into a collaboration agreement with Me...
KalVista Pharmaceuticals Provides Clinical Update on KVD900
16 November 2018 - - US-based pharmaceutical company KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has provided an update on the hereditary angioedema candidate KVD900, the company said.

...
Poxel Presents Data for PXL770 and PXL065 for the Treatment of NASH at the American Association for the Study of Liver Diseases Meeting
15 November 2018 - - French biopharmaceutical company Poxel SA (Euronext: POXEL - FR0012432516) made presentations for PXL770 and PXL065 (formerly DRX-065; acquired from DeuteRx LLC) showing prom...
Mperia Therapeutics names Chipperton as President and CEO
14 November 2018 - - Canadian macrophage-driven inflammation specialist Mperia Therapeutics' board of directors has appointed Paul Chipperton, as the company's new president and CEO, effecti...
Gilead Presents Data from Nonalcoholic Steatohepatitis Development Program for Advanced Fibrosis
13 November 2018 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has presented new data from the company's clinical development programme for advanced fibrosis due to ...
Related Headlines

Omeros Prices USD 210m Convertible Notes Offering

X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity through CXCR4 Antagonism

Synlogic Presents Preclinical Data from First Synthetic Biotic Clinical Candidate in Immuno-Oncology

Enyo Pharma Completes Phase Ib with Its FXR Agonist EYP001 and the Start of Phase II Studies in Two Indications, NASH and HBV

Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine

Five Prime Therapeutics Hires David V. Smith as Chief Financial Officer

AstraZeneca agrees to offload Alvesco (ciclesonide), Omnaris and Zetonna rights to Covis Pharma

FLX Bio Inks Clinical Trial Collaboration Agreement with Merck for Ongoing Phase 1/2 Study of FLX475

Oxurion and Beta Therapeutics enter into strategic research collaboration for development of new heparanase inhibitors to treat retinal disorders

Genkyotex Meets Both Primary and Secondary Interim Efficacy Endpoints in Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

Verona Pharma completes patient enrolment for phase two trial of RPL554

OSE Immunotherapeutics Regains Worldwide Rights to its CD28 antagonist FR104 from Janssen Biotech

Omeicos Therapeutics Closes EUR 17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation

NuMedii names new vice president, Research

Adagene treats first patient with ADG-106 in the US & announces ADG-106 IND filing in China